HEALTH & WEALTH

The best years in venture capital overlap perfectly with big crises | Health & Wealth #12

Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas to invest in, why IPOs are not a prefered exit option for Sunstone’s investments and why venture capital firms usually thrive in times of crisis.

YouTube video

BIOSTOCK STUDIO

AlZecure Pharma

Demensen ökar i takt med att vi blir äldre – AlzeCure...

Opiodkris och en åldrande befolkning, två samhällsproblem som saknar lösning. Där vill AlzeCure komma in med sin portfölj av läkemedel mot Alzheimer och smärta....

REKOMMENDERAD LÄSNING

Spago’s CEO: Advancing the Tumorad programme comes first

Spago Nanomedical’s Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad...
Kristina Torfgård, vd Alzinova

Alzinovas avgående vd kommenterar bolagets potential

Alzinova närmar sig slutfasen av den kliniska fas Ib-studien med ALZ-101 för behandling av...